A closer look at iPDM’s evidence-based benefits

Effective & efficient processes

Therapy relevant data and additional information enables accurate, efficient glucose data interpretation for earlier treatment changes

More frequent and timely therapy adjustments^1-5
Faster and more accurate decision-making⁶
Greater clinician efficiency^1,3,6
Greater clinician satisfaction^1,3,5

Improved clinical outcomes

iPDM helps reduce therapeutic inertia and improves clinical and patient-related outcomes

Reduced therapeutic inertia^1-4
Improved HbA1c with no increase in hypoglycaemia^1-3
Reduced glycaemic variability^2,3
Better postprandial control^2,3

Improved clinical outcomes

Collaboration and shared decision-making are vital for encouraging patient self-management, as well as improving adherence and treatment satisfaction

Higher treatment satisfaction^1,3,4
Improved therapy adherence^1,3
Enhanced patient understanding^3,6
Improved patient self-efficacy⁷

HbA1c: glycated hemoglobin; HCP: healthcare professionals.
1. Kulzer B, et al. Diabetes Res Clin Pract 2018;144:200 212 2. Polonsky WH et al. Diabetes Care 2011;34(2):262 267. 3. Weissmann J, et al. J Diabetes Sci Technol 2015 10(1)76 84. 4. Mora P, et al. Diabetes Technol Ther 2017;19(12):715 722. 5. Brotons C, et al. Poster presented at ATTD; 2012 Feb 8 11; Barcelona, Spain. 6. Hinnen DA, et al. J Diabetes Sci Technol 2015;9(2):293 301. 7. Kulzer B et al. Diabetes Stoffw Herz 2019; 28:325 337.